Agilent Technologies (A) has underperformed the broader market and the healthcare sector over the past year and year-to-date, despite stable fundamentals and a positive long-term outlook. Analysts maintain a “Moderate Buy” rating for the stock, with a consensus price target indicating a significant premium to current levels. The company’s stock has faced downward pressure due to market concerns over global tariffs and supply chain issues, even as it continues to meet or exceed earnings expectations.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Agilent Technologies Stock: Analyst Estimates & Ratings
Agilent Technologies (A) has underperformed the broader market and the healthcare sector over the past year and year-to-date, despite stable fundamentals and a positive long-term outlook. Analysts maintain a “Moderate Buy” rating for the stock, with a consensus price target indicating a significant premium to current levels. The company’s stock has faced downward pressure due to market concerns over global tariffs and supply chain issues, even as it continues to meet or exceed earnings expectations.